Clinical Effects of Probiotic Supplementation on Type-2 Diabetic Iraqi Patients Associated With Dyslipidemia

The consumption of probiotics is a new therapeutic strategy in preventing or delaying the onset of diabetes. Probiotics: are living, non-pathogenic micro-organisms (usually bacteria) which, when administered in sufficient numbers, exert a positive influence on host health. The present study tested the hypothesis that probiotics may improve glycemic and lipid profile in type2 diabetics with dyslipidemia of Iraqi patients. Methods: 14 of poorly controlled types 2 diabetic patients (5 male and 9 female) with dyslipidemia (age between 35 to 65 years) , with duration of diabetes and lipid profile disorder for more than 5 years ago (they were on glibenclamide a, metformine and statin therapy) enrolled in this study ,they were treated with 50 mg lactobacilli (L.acidophilus and L.plantarum) capsule, twice daily for 60 days. From fasting patients (for 12 hrs), blood samples were taken for analysis of glucose, insulin, TG, total cholesterol, LDL-C, HDL-C, % HbA1c, at zero time and each 30 days of the follow up period which continued for 2 months and the changes in the measured parameters, were compared with pretreatment readings, the data obtained were analyzed using SPSS software version 20. Results: Probiotic consumption caused a significant reduction (p < 0.05) of total serum cholesterol, TG, LDL-C and serum insulin levels, after 2month of treatment, while HDL-C levels was slightly elevated, and the Fasting serum glucose and glycated hemoglobin were reduced but not statistically significant. Results of this study showed that probiotic supplementation improved total serum cholesterol, LDL-C, TG, and serum insulin concentrations, in type 2 diabetic Iraqi patients with dyslipidemia and this may contribute to the improvement of cardiovascular disease risk factors.